Go to deals
Healthcare

Groupe Serenis has raised capital from BNP Paribas Dev., GSO Capital and Multicroissance

Groupe Serenis has raised US$8 million in equity from BNP Paribas Developpement, Credit Agricole GSO Capital and Multicroissance Banque Populaire Occitane.

Groupe Serenis operates nursing homes, residential units for disabled elderly people and geriatric clinics in the southwest of France, focusing on the high end of the dependency spectrum. A family group incorporated in 1956, Serenis is now taking a new step of development through a partnership with Kaufman&Broad, a French real estate developer, to create a network of nursing homes.

Oaklins' team in France assisted the shareholders of Serenis in this transaction to find private equity investors ready to assist and support them in this new ambitious step in the group's development.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Raphaël  Petit

Raphaël Petit

Partner

Toulouse, France
Oaklins France
 Xavier  Auvergnat

Xavier Auvergnat

Director

Toulouse, France
Oaklins France
 Alexandre  Mantion

Alexandre Mantion

Analyst

Toulouse, France
Oaklins France

Related deals

Groupe Nature acquires Winco
Consumer & Retail | Healthcare

Groupe Nature acquires Winco

Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.

Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
Consumer & Retail | Healthcare

Camelia pharmacy chain has been acquired by Medigate Management UAB

CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.

Learn more
Shield Therapeutics has raised funds
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Learn more